The actual benefit of VELETRI is substantial in PAH.
Clinical Added Value
no clinical added value
In PAH :
VELETRI (epoprostenol), a hybrid medicine based on FLOLAN and its generics which has a new pharmaceutical form extending the stability of the solution at room temperature, does not provide any improvement in actual benefit (level V,non-existent) in comparison with these proprietary medicinal products.
Listen
